Aeglea BioTherapeutics, Inc./$SYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
73
Website
SYRE Metrics
BasicAdvanced
$1B
-
-$3.01
2.80
-
Price and volume
Market cap
$1B
Beta
2.8
52-week high
$21.03
52-week low
$10.91
Average daily volume
631K
Financial strength
Current ratio
8.061
Quick ratio
7.991
Profitability
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-25.34%
Return on equity (TTM)
-65.82%
Valuation
Price to book
3.13
Price to tangible book (TTM)
3.13
Price to free cash flow (TTM)
-5.292
Free cash flow yield (TTM)
-18.90%
Free cash flow per share (TTM)
-3.207
Growth
Earnings per share change (TTM)
-55.92%
3-year earnings per share growth (CAGR)
-53.91%
10-year earnings per share growth (CAGR)
-40.30%
Bulls say / Bears say
Spyre Therapeutics has a strong financial position with $205 million in cash and equivalents as of September 30, 2023, providing a runway into 2026, which supports sustained research and development efforts. (nasdaq.com)
The appointment of Cameron Turtle, DPhil, as CEO, along with industry veterans Jeffrey Albers and Laurie Stelzer to the Board, brings experienced leadership to drive the company's strategic initiatives. (nasdaq.com)
Spyre's pipeline includes promising candidates like SPY001 and SPY002, targeting α4β7 and TL1A respectively, both on track to enter clinical studies in 2024, potentially leading to innovative treatments for inflammatory bowel disease. (nasdaq.com)
The biotechnology sector is highly competitive, and Spyre's success depends on the clinical and commercial success of its pipeline, which is still in early stages, posing inherent risks. (nasdaq.com)
Despite a strong cash position, the company may require additional funding to bring its therapies to market, which could lead to shareholder dilution or increased debt. (nasdaq.com)
The recent reverse stock split at a 1-for-25 ratio indicates previous challenges in maintaining Nasdaq listing requirements, which may reflect underlying financial or operational issues. (aeglea.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $1B as of August 01, 2025.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of August 01, 2025.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 2.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.